ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

balstilimab

Also written as “Balstilimab”, “AGEN2034” and “Balstilimab + Zalifrelimab”.

Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms · Neoplasms · Hemangiosarcoma, led by 3 companies.

Drug pageBalstilimab: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 4, 202110 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenus81 open or runningphase 3since Jun 4, 2021Mar 27, 2017Sep 2027phase 2 · NCT05608044
ImmunoGenesisits history only11 open or runningphase 2since Jan 9, 2025Jan 9, 2025Oct 2027phase 2 · NCT06782555
Rottapharm Biotechits history only11 open or runningphase 2since Jan 20, 2022Jan 20, 2022Dec 2026phase 2 · NCT05205330

Also a collaborator on its studies: Betta Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Agenus only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2017First study: phase 2 study in Uterine Cervical NeoplasmsFirst studyNCT03104699 · 211 enrolled · United States, Australia, Belgium and more
  2. Jan 19, 2018Phase 2 study in Uterine Cervical NeoplasmsNCT03495882 · 175 enrolled · United States, Australia, Brazil and more
  3. Dec 9, 2018Named balstilimabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, AGEN2034
  4. Mar 19, 2019Phase 2 study in Uterine Cervical NeoplasmsNCT03894215 · 211 enrolled · United States, Brazil, Mexico and more
  5. Sep 18, 2019Phase 1 study in NeoplasmsNCT04156100 · 19 enrolled · United States
  6. Oct 16, 2020Phase 2 study in HemangiosarcomaNCT04607200
  7. Jun 4, 2021Phase 3 study in Uterine Cervical NeoplasmsNCT04943627 · United States, Armenia
  8. Aug 27, 2021Phase 2 study in Uterine Cervical NeoplasmsNCT05033132 · China
  9. Nov 1, 2022Phase 2 study in Colorectal NeoplasmsNCT05608044 · 234 enrolled · United States, Belgium, Brazil and more

Ahead

  1. Sep 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT05608044

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 8 Agenus leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05608044Colorectal Neoplasms · United States, Belgium, Brazil and more2Active, not recruitingSep 2027234
NCT05033132Uterine Cervical Neoplasms · China2WithdrawnDec 30, 20240
NCT04943627Uterine Cervical Neoplasms · United States, Armenia3WithdrawnOct 22, 20210
NCT04607200Hemangiosarcoma2WithdrawnSep 13, 20210
NCT04156100Neoplasms · United States1TerminatedApr 8, 202119
NCT03894215Uterine Cervical Neoplasms · United States, Brazil, Mexico and more2TerminatedMar 26, 2025211
NCT03495882Uterine Cervical Neoplasms · United States, Australia, Brazil and more2CompletedJul 15, 2022175
NCT03104699Uterine Cervical Neoplasms · United States, Australia, Belgium and more2CompletedJun 15, 2022211

How it is read

Names in the registry

  • “Balstilimab”, 4 entries
  • “AGEN2034”, 4 entries
  • “Balstilimab + Zalifrelimab”, 1 entry
  • “Balstilimab (BAL)”, 1 entry
  • “AGEN1223 and balstilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.